Antibody infusion treatment offers peace of mind for people at high risk for severe illness from COVID-19
Monoclonal antibodies, laboratory-made proteins that effectively boost the immune system’s ability to fight the COVID-19 virus, is shown to significantly reduce the risk of hospitalization or death in people age 65 or older, and those with certain chronic medical conditions, such as diabetes, heart disease, or obesity. Monoclonal antibody infusion received an emergency use authorization from the U.S. Food and Drug Administration in late 2020, following successful clinical trials at Penn Medicine and other institutions.
FULL STORY AT Penn Medicine News →